All News

Prosthesis ups and downs.

Every person recalls vividly when they were given the diagnosis of cancer.

Accepting what is fact and being OK with the reality of an awful illness

A drug combination is showing promise in mouse models and may lead to a new treatment option for patients with glioblastoma.

Imfinzi (durvalumab) may change the treatment paradigm for some patients with urothelial carcinoma.

A recently-published Canadian study examined the possible correlation between work-related stress and cancer.

This is probably not about what you’re thinking.

Being able to laugh during difficult situations is a good thing especially for those who've suffered the trauma of breast cancer. Here's one woman's experience learning to laugh at the loss of her breasts.

Kale is incredibly popular. It's everywhere.

JCAR017 had promising complete response and objective response rates in treating patients with diffuse large B-cell lymphoma (DLBCL) in a recently presented study.

Reforms are needed high up within the drug distribution chain, concluded a panel of pharmaceutical professionals at the Oncology Market Access & Pricing conference held in Philadelphia this week by eyeforpharma.

There is hot debate over whether full-body skin exams should be done each year to help in early detection of both non-melanoma and melanoma skin cancers.

How decreasing my pace has made me acutely aware of the outside noise that distracts us from the life’s most important things, which aren’t things at all.

Green can be a beautiful color full of life, but it can also be the color of chemotherapy.

Apreciating all the positives amongst the disease of cancer

Three times comments about my cancer made me say, "Huh?"

The Food and Drug Administration (FDA) granted an approval to Darzalex (daratumumab) for use in combination with Pomalyst (pomalidomide) and dexamethasone for patients who have multiple myeloma who have two or more prior therapies, including a proteasome inhibitor and Revlimid (lenalidomide).

Opdivo had promising response rates in a recent trial testing the treatment in patients with relapsed or refractory Hodgkin lymphoma.

Taking the good with the bad and living life despite cancer

Taking back control of your life with small wins.

The term "palliative care" used to mean keeping a patient comfortable until he or she died. Today it has evolved into a discipline to help patients live longer and better.

When used as a neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC), split-dose of gemcitabine and cisplatin has a beneficial response and a high safety profile, according to a study presented at the 2017 American Urological Association Annual Meeting.

Pairing two drugs that have shown to be effective in treating lymphoma might be the next step for mantle cell lymphoma treatment.

The possibility of carrying the BRCA gene mutation can be concerning to women who've been diagnosed with cancer especially when their children may eventually be affected.

Eating well is hard. Diet is personal.

We must remember what happened but also move forward.

Superior progression-free survival (PFS) was seen in patients with ovarian cancer who previously had a partial response (PR) to platinum-based therapy when they took Zejula (niraparib). This response was seen in patients with or without germline BRCA mutations, according to data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.

Progression-free survival (PFS) was not significantly improved with the combination of dalantercept plus Inlyta (axitinib) in patients with advanced renal cell carcinoma (RCC) compared with placebo, according to the results from the phase 2 DART trial.